{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:16:55Z","timestamp":1790662615716,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013751","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000}}],"reference-count":244,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013751.pub2","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T11:12:50Z","timestamp":1661425970000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease"],"prefix":"10.1002","volume":"2022","author":[{"given":"Patrizia","family":"Natale","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation; University of Bari; Bari Italy"},{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Sciences; University of Foggia; Foggia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suetonia C","family":"Palmer","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Otago Christchurch; Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Jaure","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth M","family":"Hodson","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinella","family":"Ruospo","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation; University of Bari; Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess E","family":"Cooper","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre","family":"Hahn","sequence":"additional","affiliation":[{"name":"Department of Nephrology; The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria M","family":"Saglimbene","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation; University of Bari; Bari Italy"},{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"},{"name":"College of Medicine and Public Health; Flinders University; Adelaide Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation; University of Bari; Bari Italy"},{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD013751.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000454818","article-title":"Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects","volume":"45","author":"Akizawa","year":"2017","journal-title":"American Journal of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0002|cit2","first-page":"818A","article-title":"A 4 -week dose response study of the hypoxia inducible factor-prolyl hydroxylase inhibitor GSK1278863 in Japanese anemic haemodialysis subjects [abstract no: SA-PO819]","volume":"26","author":"Endo","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0003|cit3","unstructured":"Study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease clinicaltrials.gov\/show\/NCT02019719"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0004|cit4","first-page":"7B","article-title":"Roxadustat for the treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis [abstract no: FR-PO1142]","volume":"27","author":"Akizawa","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD013751.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1007\/s12325-019-00943-4","article-title":"Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial","volume":"36","author":"Akizawa","year":"2019","journal-title":"Advances in Therapy"},{"issue":"4","key":"10.1002\/14651858.CD013751.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1681\/ASN.2021010051","article-title":"Authors' Reply","volume":"32","author":"Akizawa","year":"2021","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0007|cit7","first-page":"B4","article-title":"Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) conversion study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-PO1151]","volume":"29","author":"Akizawa","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD013751.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2019060623","article-title":"Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan","volume":"31","author":"Akizawa","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD013751.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/1744-9987.13609","article-title":"Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients","volume":"25","author":"Akizawa","year":"2021","journal-title":"Therapeutic Apheresis & Dialysis"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0010|cit10","unstructured":"A study of intermittent oral dosing of ASP1517 in hemodialysis chronic kidney disease patients with anemia www.clinicaltrials.astellas.com\/study\/?pid=1517-CL-0307"},{"issue":"4","key":"10.1002\/14651858.CD013751.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1681\/ASN.2020111664","article-title":"Roxadustat for renal anemia in ESRD from PKD patients: is it safe enough?","volume":"32","author":"Liu","year":"2021","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1681\/ASN.20203110S1134a","article-title":"Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]","volume":"31","author":"Nguyen","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013751.pub2-BIB0013|cit13","first-page":"iii102","article-title":"Ophthalmological effects of roxadustat in the treatment of anaemia in chronic kidney disease patients on dialysis in a phase 3, randomised, double-blind, active-comparator conversion study [abstract no: MO002]","volume":"35","author":"Sepah","year":"2020","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD013751.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2215\/CJN.16011219","article-title":"Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial","volume":"15","author":"Akizawa","year":"2020","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013751.pub2-BIB0015|cit15","first-page":"a350","article-title":"Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: A randomized, double-blind, phase 3 trial [abstract no: SaO036]","volume":"34","author":"Ozeki","year":"2019","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.ekir.2021.03.259","article-title":"A phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in non-dialysis-dependent (NDD) patients with anemia in chronic kidney disease (CKD) [abstract no: POS-244]","volume":"6","author":"Akizawa","year":"2021","journal-title":"Kidney International Reports"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1681\/ASN.20203110S1134c","article-title":"A phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in non-dialysis-dependent (NDD) patients with anemia in CKD [abstract no: PO0269]","volume":"31","author":"Akizawa","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1681\/ASN.20203110S1134a","article-title":"Ophthalmological effects of roxadustat in the treatment of anemia in dialysis-dependent and non-dialysis-dependent CKD patients: findings from two phase 3 studies [abstract no: PO0267]","volume":"31","author":"Nguyen","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD013751.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.ekir.2021.04.003","article-title":"Phase 3 study of roxadustat to treat anemia in non-dialysis-dependant CKD","volume":"6","author":"Akizawa","year":"2021","journal-title":"Kidney International Reports"},{"issue":"9","key":"10.1002\/14651858.CD013751.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1159\/000519043","article-title":"Factors affecting doses of roxadustat versus darbepoetin alfa for anemia in nondialysis patients","volume":"52","author":"Akizawa","year":"2021","journal-title":"American Journal of Nephrology"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0021|cit21","unstructured":"Roxadustat in the treatment of anemia in chronic kidney disease patients not requiring dialysis www.trialsummaries.com\/Study\/StudyDetails?id=14384&tenant=MT_AST_9011 2019"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0022|cit22","first-page":"822","article-title":"Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract no: SA-PO225]","volume":"30","author":"Esposito","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1681\/ASN.20203110S12a","article-title":"Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]","volume":"31","author":"Pecoits-Filho","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1681\/ASN.20203110S1133a","article-title":"Roxadustat treatment corrects anemia to hemoglobin (HB) values \u226510 g\/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]","volume":"31","author":"Rastogi","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD013751.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/ndt\/gfab057","article-title":"Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS)","volume":"36","author":"Shutov","year":"2021","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0026|cit26","first-page":"132","article-title":"Roxadustat favorably modifies iron indices in patients with non-dialysis-dependent CKD-related anemia [abstract no: PO0262]","volume":"31","author":"Coyne","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD013751.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ekir.2020.11.034","article-title":"Roxadustat for CKD-related anemia in non-dialysis patients","volume":"6","author":"Coyne","year":"2021","journal-title":"Kidney International Reports"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0028|cit28","first-page":"822","article-title":"ANDES: A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in CKD patients not on dialysis [abstract no: SA-PO0228]","volume":"30","author":"Coyne","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1681\/ASN.20203110S12a","article-title":"Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]","volume":"31","author":"Pecoits-Filho","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1681\/ASN.20203110S1133a","article-title":"Roxadustat treatment corrects anemia to hemoglobin (HB) values \u226510 g\/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]","volume":"31","author":"Rastogi","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD013751.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/ndt\/gfab065","article-title":"Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial","volume":"37","author":"Singh","year":"2021","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1681\/ASN.20203110S13a","article-title":"Regional variation of erythropoietin-stimulating agent hyporesponsiveness in the global daprodustat dialysis study (ASCEND-D) [abstract no: TH-OR08]","volume":"31","author":"Singh","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"25","key":"10.1002\/14651858.CD013751.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","article-title":"Daprodustat for the treatment of anemia in patients undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1681\/ASN.20213210S1184d","article-title":"Daprodustat is noninferior to darbepoetin alfa in treating anemia in incident dialysis patients [abstract no: PO0465]","volume":"32","author":"Singh","year":"2021","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013751.pub2-BIB0035|cit35","first-page":"i334","article-title":"ASCEND-ND: Study design and baseline characteristics","volume":"36","author":"Perkovic","year":"2021","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"25","key":"10.1002\/14651858.CD013751.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the treatment of anemia in patients not undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1681\/ASN.20213210S136b","article-title":"Effects of daprodustat on hemoglobin and quality of life in patients with CKD: results of the ascend-NHQ randomized, double-blind, placebo-controlled trial [abstract no: FR-OR53]","volume":"32","author":"Johansen","year":"2021","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1681\/ASN.20213210S1191b","article-title":"ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three times weekly in hemodialysis patients [abstract no: PO0487]","volume":"32","author":"Coyne","year":"2021","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0039|cit39","first-page":"95A","article-title":"FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3\/4 CKD patients [abstract no: SA-FC416]","volume":"21","author":"Besarab","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD013751.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients","volume":"30","author":"Besarab","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD013751.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1053\/j.ajkd.2015.11.021","article-title":"A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2a randomized trial","volume":"67","author":"Brigandi","year":"2016","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0042|cit42","first-page":"662A","article-title":"Induction of erythropoiesis in anemic patients by prolylhydroxylase inhibitor in a repeat dose, randomized placebo controlled trial [abstract no: SA-PO117]","volume":"23","author":"Brigandi","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0043|cit43","first-page":"662A","article-title":"Modulation of hepcidin by prolylhydroxylase inhibitor in randomized trials [abstract no: SA-PO118]","volume":"23","author":"Brigandi","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0044|cit44","first-page":"B5","article-title":"A phase 3, randomized, open-label, active-controlled study of efficacy and safety of roxadustat for treatment of anemia in subjects with CKD on dialysis [abstract no: TH-PO1152]","volume":"29","author":"Chen","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD013751.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD013751.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0047|cit47","first-page":"B5","article-title":"A phase 3, randomized, double-blind, placebo-controlled study of efficacy and safety of roxadustat (FG-4592) for treatment of anemia in subjects with CKD not on dialysis [abstract no: TH-PO1153]","volume":"29","author":"Chen","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD013751.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","article-title":"Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China","volume":"32","author":"Chen","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD013751.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","article-title":"Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China","volume":"32","author":"Chen","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0050|cit50","first-page":"38A","article-title":"A randomized, double-blind, placebo controlled trial of FG-4592 for correction of anemia in subjects with chronic kidney disease in China [abstract no: FR-OR011]","volume":"24","author":"Qian","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013751.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"i457","DOI":"10.1093\/ndt\/gfy104.SP334","article-title":"Iron regulation by molidustat, bay 85-3934, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor in patients with chronic kidney disease [abstract no: SP334]","volume":"33","author":"Akizawa","year":"2018","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD013751.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000502012","article-title":"Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease","volume":"143","author":"Akizawa","year":"2019","journal-title":"Nephron"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013751.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1093\/ndt\/gfw123.04","article-title":"Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]","volume":"31","author":"Macdougall","year":"2016","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD013751.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2215\/CJN.02510218","article-title":"Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]","volume":"14","author":"Macdougall","year":"2019","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0055|cit55","first-page":"413A","article-title":"DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD\/ESRD [abstract no: FR-PO219]","volume":"24","author":"Macdougall","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD013751.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000502012","article-title":"Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease","volume":"143","author":"Akizawa","year":"2019","journal-title":"Nephron"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013751.pub2-BIB0057|cit57","first-page":"i193","article-title":"Safety and efficacy of molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SP309]","volume":"31","author":"Macdougall","year":"2016","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013751.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1093\/ndt\/gfw123.04","article-title":"Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]]","volume":"31","author":"Macdougall","year":"2016","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD013751.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2215\/CJN.02510218","article-title":"Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]","volume":"14","author":"Macdougall","year":"2019","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0060|cit60","first-page":"413A","article-title":"DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD\/ESRD [abstract no: FR-PO219]","volume":"24","author":"Macdougall","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD013751.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000502012","article-title":"Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease","volume":"143","author":"Akizawa","year":"2019","journal-title":"Nephron"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013751.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1093\/ndt\/gfw123.04","article-title":"Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract no: SO036]","volume":"31","author":"Macdougall","year":"2016","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD013751.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2215\/CJN.02510218","article-title":"Effects of molidustat in the treatment of anemia in CKD [Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524]","volume":"14","author":"Macdougall","year":"2019","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0064|cit64","first-page":"413A","article-title":"DIALOGUE phase 2 program for BAY85-3934 a HIF-PH inhibitor with daily oral treatment in anemic patients suffering from CKD\/ESRD [abstract no: FR-PO219]","volume":"24","author":"Macdougall","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1681\/ASN.20203110S11b","article-title":"Roxadustat for the treatment of anemia in CKD patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: TH-OR02]","volume":"31","author":"Barratt","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD013751.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","article-title":"Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active-controlled study (DOLOMITES)","volume":"36","author":"Barratt","year":"2021","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013751.pub2-BIB0067|cit67","first-page":"iii101","article-title":"Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active controlled study [abstract no: MO001]","volume":"35","author":"Barratt","year":"2020","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/j.ekir.2021.03.262","article-title":"Roxadustat for the treatment of anemia in chronic kidney disease (CKD) patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study [abstract no: Pos-247]","volume":"6","author":"Barratt","year":"2021","journal-title":"Kidney International Reports"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0069|cit69","first-page":"5","article-title":"HIMALAYAS: a phase 3, randomized, open-label, active-controlled study of the efficacy and safety of roxadustat in the treatment of anemia in incident-dialysis patients [abstract no: TH-OR021]","volume":"30","author":"Provenzano","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD013751.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","article-title":"Roxadustat for anemia in patients with end-stage renal disease incident to dialysis","volume":"36","author":"Provenzano","year":"2021","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013751.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"i316","DOI":"10.1093\/ndt\/gfy104.SaO004","article-title":"Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]","volume":"33","author":"Cizman","year":"2018","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD013751.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ckj\/sfy013","article-title":"Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease","volume":"12","author":"Holdstock","year":"2019","journal-title":"Clinical Kidney Journal"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0073|cit73","first-page":"304A","article-title":"Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]","volume":"27","author":"Holdstock","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013751.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"i316","DOI":"10.1093\/ndt\/gfy104.SaO004","article-title":"Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]","volume":"33","author":"Cizman","year":"2018","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD013751.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ckj\/sfy013","article-title":"Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease","volume":"12","author":"Holdstock","year":"2019","journal-title":"Clinical Kidney Journal"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0076|cit76","first-page":"304A","article-title":"Daprodustat, a HIF-prolyl-hydroxylase inhibitor, increases and maintains hemoglobin over 24 weeks in anemic chronic kidney disease subjects [abstract no: TH-PO908]","volume":"27","author":"Holdstock","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD013751.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jfma.2021.06.004","article-title":"Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial","volume":"121","author":"Hou","year":"2021","journal-title":"Journal of the Formosan Medical Association"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1681\/ASN.20213210S1184c","article-title":"Vadadustat for treatment of anemia in patients with dialysis-dependent CKD receiving peritoneal dialysis [abstract no: PO0464]","volume":"32","author":"Chertow","year":"2021","journal-title":"Journal of the American Society of Nephrology"},{"issue":"17","key":"10.1002\/14651858.CD013751.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","article-title":"Safety and efficacy of vadadustat for anemia in patients undergoing dialysis","volume":"384","author":"Eckardt","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD013751.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/ndt\/gfaa204","article-title":"Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials","volume":"36","author":"Eckardt","year":"2020","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1681\/ASN.20203110S11a","article-title":"Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD [abstract no: TH-OR01]","volume":"31","author":"Eckardt","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1681\/ASN.20213210S1184b","article-title":"Thromboembolic events with vadadustat vs. darbepoetin alfa for anemia treatment in patients with dialysis-dependent CKD [abstract no: PO0463]","volume":"32","author":"Parfrey","year":"2021","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013751.pub2-BIB0083|cit83","first-page":"i325","article-title":"Hematologic efficacy of vadadustat for anemia in patients with kidney failure on dialysis [abstract no: MO529]","volume":"36","author":"Winkelmayer","year":"2021","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1681\/ASN.20213210S1182c","article-title":"Iron-related outcomes in patients with dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0457]","volume":"32","author":"Winkelmayer","year":"2021","journal-title":"Journal of the American Society of Nephrology"},{"issue":"17","key":"10.1002\/14651858.CD013751.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","article-title":"Safety and efficacy of vadadustat for anemia in patients undergoing dialysis","volume":"384","author":"Eckardt","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD013751.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/ndt\/gfaa204","article-title":"Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials","volume":"36","author":"Eckardt","year":"2020","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1681\/ASN.20203110S11a","article-title":"Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD [abstract no: TH-OR01]","volume":"31","author":"Eckardt","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1681\/ASN.20213210S1182c","article-title":"Iron-related outcomes in patients with dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0457]","volume":"32","author":"Winkelmayer","year":"2021","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013751.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"i316","DOI":"10.1093\/ndt\/gfy104.SaO004","article-title":"Ocular safety profile of daprodustat: results of two 24 week studies [abstract no: SAO004]","volume":"33","author":"Cizman","year":"2018","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0090|cit90","first-page":"93A","article-title":"Daprodustat, a HIF-prolyl-hydroxylase inhibitor, maintains hemoglobin levels over 24 weeks in anemic hemodialysis subjects switching from recombinant human erythropoietin. [abstract no: SA-OR114]","volume":"27","author":"Cobitz","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD013751.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/ckj\/sfy014","article-title":"Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis","volume":"12","author":"Meadowcroft","year":"2019","journal-title":"Clinical Kidney Journal"},{"issue":"6","key":"10.1002\/14651858.CD013751.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"e026602","DOI":"10.1136\/bmjopen-2018-026602","article-title":"Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: Design and rationale of three phase III studies","volume":"9","author":"Akizawa","year":"2019","journal-title":"BMJ Open"},{"issue":"10","key":"10.1002\/14651858.CD013751.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"2604\u201316","DOI":"10.1016\/j.ekir.2021.07.015","article-title":"Molidustat for Japanese patients with renal anemia receiving dialysis","volume":"6","author":"Akizawa","year":"2021","journal-title":"Kidney International Reports"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"B4","DOI":"10.1681\/ASN.20203110S1B4a","article-title":"Results from a phase 3 study comparing the efficacy and safety of molidustat vs. Darbepoetin Alfa in patients receiving hemodialysis and treated with erythropoiesis-stimulating agents (ESAS) [abstract no: PO22623]","volume":"31","author":"Akizawa","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10-11","key":"10.1002\/14651858.CD013751.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1159\/000518071","article-title":"Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients: a randomized, phase 3 trial","volume":"52","author":"Yamamoto","year":"2021","journal-title":"American Journal of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD013751.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"e026704","DOI":"10.1136\/bmjopen-2018-026704","article-title":"Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies","volume":"9","author":"Yamamoto","year":"2019","journal-title":"BMJ Open"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013751.pub2-BIB0097|cit97","first-page":"iii2177","article-title":"To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are not treated with erythropoiesis stimulating agents: MIYABI ND-C [abstract no: P1866]","volume":"35","author":"Yamamoto","year":"2020","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"10-11","key":"10.1002\/14651858.CD013751.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1159\/000518072","article-title":"Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis-stimulating agents: a randomized, open-label, phase 3 study","volume":"52","author":"Yamamoto","year":"2021","journal-title":"American Journal of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD013751.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"e026704","DOI":"10.1136\/bmjopen-2018-026704","article-title":"Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies","volume":"9","author":"Yamamoto","year":"2019","journal-title":"BMJ Open"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013751.pub2-BIB0100|cit100","first-page":"iii2179","article-title":"To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are treated with erythropoiesis stimulating agents: Miyabi ND-M [Abstract no: P1868]","volume":"35","author":"Yamamoto","year":"2020","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD013751.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/ndt\/gfab055","article-title":"Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a phase 3, multicenter, randomized, double-blind study","volume":"36","author":"Nangaku","year":"2021","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0102|cit102","first-page":"6","article-title":"Randomized, double-blinded, active-controlled (darbepoetin alfa), phase 3 study of vadadustat in CKD patients with anemia on hemodialysis in Japan [abstract no: TH-OR024]","volume":"30","author":"Nangaku","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0103|cit103","first-page":"823","article-title":"Randomized, open-label, active-controlled (darbepoetin alfa), phase 3 study of vadadustat for treating anemia in non-dialysis-dependent CKD patients in Japan [abstract no: SA-PO229]","volume":"30","author":"Nangaku","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD013751.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1681\/ASN.2020091311","article-title":"Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD","volume":"32","author":"Nangaku","year":"2021","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0105|cit105","unstructured":"A 52-week, Phase III, open-label, multi-center study to evaluate efficacy and safety of GSK1278863 in Japanese non-dialysis and peritoneal dialysis subjects with anemia associated with chronic kidney disease [study protocol] www.clinicaltrials.gov\/ProvidedDocs\/63\/NCT02791763\/Prot_000.pdf"},{"issue":"1","key":"10.1002\/14651858.CD013751.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000513103","article-title":"Daprodustat compared with epoetin beta pegol for anemia in Japanese patients not on dialysis: a 52-week randomized open-label phase 3 trial","volume":"52","author":"Nangaku","year":"2021","journal-title":"American Journal of Nephrology"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0107|cit107","unstructured":"A study to investigate the effect of ASP1517 after intermittent oral dosing in dialysis chronic kidney disease patients with anemia compared with darbepoetin as a reference drug www.trialsummaries.com\/Study\/StudyDetails?id=14175&tenant=MT_AST_9011; www.clinicaltrials.gov\/ct2\/show\/NCT01888445"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0108|cit108","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa060","article-title":"Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients","author":"Nangaku","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0109|cit109","first-page":"171","article-title":"Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]","volume":"29","author":"Nangaku","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD013751.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/j.ajkd.2020.02.354","article-title":"Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]","volume":"75","author":"Solinsky","year":"2020","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0111|cit111","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa060","article-title":"Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients","author":"Nangaku","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0112|cit112","first-page":"171","article-title":"Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]","volume":"29","author":"Nangaku","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD013751.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/j.ajkd.2020.02.354","article-title":"Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]","volume":"75","author":"Solinsky","year":"2020","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0114|cit114","unstructured":"A phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis [clinical study protocol V6; 31 August 2018] www.clinicaltrials.gov\/ProvidedDocs\/27\/NCT02174627\/Prot_000.pdf"},{"issue":"6","key":"10.1002\/14651858.CD013751.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1681\/ASN.2021020204","article-title":"On the increased event rate of urinary tract infection and pneumonia in CKD patients treated with roxadustat for anemia","volume":"32","author":"Eleftheriadis","year":"2021","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0116|cit116","first-page":"6","article-title":"OLYMPUS: a phase 3, randomized, double-blind, placebo-controlled, international study of roxadustat efficacy in patients with non-dialysis-dependent (NDD) CKD and anemia [abstract no: TH-OR023]","volume":"30","author":"Fishbane","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD013751.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1681\/ASN.2020081150","article-title":"Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study","volume":"32","author":"Fishbane","year":"2021","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD013751.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1681\/ASN.2021030334","article-title":"Authors' Reply","volume":"32","author":"Fishbane","year":"2021","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1681\/ASN.20203110S12a","article-title":"Roxadustat treatment results in consistent improvements in hemoglobin (Hb) vs. placebo: an analysis of three multinational randomized clinical trials in patients with non-dialysis-dependent CKD (NDD-CKD) [abstract no: TH-OR05]","volume":"31","author":"Pecoits-Filho","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1681\/ASN.20203110S1133a","article-title":"Roxadustat treatment corrects anemia to hemoglobin (HB) values \u226510 g\/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) [abstract no: PO0264]","volume":"31","author":"Rastogi","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0121|cit121","first-page":"237A","article-title":"AKB-6548 demonstrates controlled hemogloblin (HGB) response in a phase 2b study for the treatment of anemia in patients with chronic kidney disease not on dialysis (ND-CKD) [abstract no: TH-PO649]","volume":"26","author":"Haase","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0122|cit122","first-page":"304A","article-title":"Efficacy and dose requirements of vadadustat are independent of systemic inflammation and prior erythropoiesis-stimulating agent(ESA) dose in patients with non-dialysis dependent chronic kidney disease (NDD-CKD) [abstract no: TH-PO907]","volume":"27","author":"Haase","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013751.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"iii8","DOI":"10.1093\/ndt\/gfv138.02","article-title":"AKB-6548, a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) for the treatment of anemia in patients with chronic kidney disease not on dialysis (ND-CKD) [abstract no: FO015]","volume":"30","author":"Pergola","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD013751.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","article-title":"Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease","volume":"90","author":"Pergola","year":"2016","journal-title":"Kidney International"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0125|cit125","first-page":"11A","article-title":"Hemoglobin (HGB) response in a phase 2b study of AKB-6548 for the treatment of anemia in patients with non-dialysis dependant chronic kidney disease (NDD-CKD). [abstract no: TH-OR038]","volume":"26","author":"Spinowitz","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"16","key":"10.1002\/14651858.CD013751.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1056\/NEJMc2110095","article-title":"Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease","volume":"385","author":"Bunn","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013751.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2020.10.068","article-title":"Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics","volume":"235","author":"Chertow","year":"2021","journal-title":"American Heart Journal"},{"issue":"17","key":"10.1002\/14651858.CD013751.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in patients with anemia and non-dialysis-dependent CKD","volume":"384","author":"Chertow","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"B2","DOI":"10.1681\/ASN.20203110S1B2a","article-title":"Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR54]","volume":"31","author":"Chertow","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1681\/ASN.20213210S1190a","article-title":"Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin Alfa [abstract no: PO0482]","volume":"32","author":"Koury","year":"2021","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1681\/ASN.20213210S1184a","article-title":"Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]","volume":"32","author":"McCullough","year":"2021","journal-title":"Journal of the American Society of Nephrology"},{"issue":"16","key":"10.1002\/14651858.CD013751.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1056\/NEJMc2110095","article-title":"Vadadustat for anemia in patients with dialysis-dependent or non-dialysis-dependent chronic kidney disease","volume":"385","author":"Bunn","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013751.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2020.10.068","article-title":"Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: design and baseline characteristics","volume":"235","author":"Chertow","year":"2021","journal-title":"American Heart Journal"},{"issue":"17","key":"10.1002\/14651858.CD013751.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in patients with anemia and non-dialysis-dependent CKD","volume":"384","author":"Chertow","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"B2","DOI":"10.1681\/ASN.20203110S1B2a","article-title":"Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: FR-OR5]","volume":"31","author":"Chertow","year":"2020","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1681\/ASN.20213210S1190a","article-title":"Iron-related outcomes in patients with non-dialysis-dependent CKD randomized to vadadustat vs. darbepoetin alfa [abstract no: PO0482]","volume":"32","author":"Koury","year":"2021","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1681\/ASN.20213210S1184a","article-title":"Assessment of thromboembolic events with vadadustat vs. darbepoetin alfa for treatment of anemia in patients with non-dialysis-dependent CKD [abstract no: PO0462]","volume":"32","author":"McCullough","year":"2021","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD013751.pub2-BIB0138|cit138","first-page":"A80","article-title":"FG2216, a novel oral HIF-PHI, stimulates erythropoiesis and increases hemoglobin concentration in patients with non-dialysis CKD [abstract no: 212]","volume":"51","author":"Provenzano","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD013751.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"A78","DOI":"10.1053\/j.ajkd.2013.02.254","article-title":"Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor FG-2216 increases Hb without FE depletion in the absence of IV Fe [abstract no: 249]","volume":"61","author":"Provenzano","year":"2013","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0140|cit140","first-page":"428A","article-title":"FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), maintains hemoglobin levels and lowers cholesterol in hemodialysis patients: phase 2 comparison with epoetin alfa [abstract no: FR-PO257]","volume":"23","author":"Provenzano","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD013751.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0142|cit142","first-page":"428A","article-title":"FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), maintains hemoglobin levels and lowers cholesterol in hemodialysis patients: phase 2 comparison with epoetin alfa [abstract no: FR-PO257]","volume":"23","author":"Provenzano","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD013751.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0144|cit144","unstructured":"Roxadustat in the treatment of anemia in end stage renal disease (ESRD) patients on stable dialysis www.trialsummaries.com\/Study\/StudyDetails?id=14380&tenant=MT_AST_9011"},{"issue":"10","key":"10.1002\/14651858.CD013751.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1007\/s12325-021-01904-6","article-title":"Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active-controlled study (PYRENEES)","volume":"38","author":"Csiky","year":"2021","journal-title":"Advances in Therapy"},{"issue":"Suppl 248","key":"10.1002\/14651858.CD013751.pub2-BIB0146|cit146","first-page":"21","article-title":"Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis","volume":"150","author":"Esposito","year":"2020","journal-title":"Swiss Medical Weekly"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0147|cit147","first-page":"822","article-title":"Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract no: SA-PO225]","volume":"30","author":"Esposito","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0148|cit148","unstructured":"A phase 3, multicenter, randomized, open-label, active-controlled study of the safety and efficacy of roxadustat in the treatment of anemia in dialysis patients [Clinical study protocol v8.0 19 September 2018] www.clinicaltrials.gov\/ProvidedDocs\/31\/NCT02174731\/Prot_000.pdf"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0149|cit149","first-page":"6","article-title":"ROCKIES: an international, phase 3, randomized, open-label, active-controlled study of roxadustat for anemia in dialysis-dependent CKD patients [abstract no: TH-OR022]","volume":"30","author":"Fishbane","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD013751.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.ekir.2021.04.007","article-title":"A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study","volume":"6","author":"Charytan","year":"2021","journal-title":"Kidney International Reports"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0151|cit151","first-page":"822","article-title":"SIERRAS: A phase 3, open-label, randomized, active-controlled study of the efficacy and safety of roxadustat in the maintenance treatment of anemia in subjects with ESRD on stable dialysis [abstract no: SA-PO227]","volume":"30","author":"Charytan","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0152|cit152","first-page":"B4","article-title":"Phase 3 study to compare the efficacy and safety of enarodustat (JTZ-951), an oral HIF-PH inhibitor, with darbepoetin alfa in anemic patients with CKD receiving maintenance hemodialysis [abstract no: TH-PO1186]","volume":"30","author":"Akizawa","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD013751.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1159\/000517053","article-title":"A phase 3 study of enarodustat (JTZ-951) in Japanese hemodialysis patients for treatment of anemia in chronic kidney disease: SYMPHONY HD study","volume":"7","author":"Akizawa","year":"2021","journal-title":"Kidney Diseases"},{"issue":"7","key":"10.1002\/14651858.CD013751.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.ekir.2021.04.037","article-title":"A phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study","volume":"6","author":"Akizawa","year":"2021","journal-title":"Kidney International Reports"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013751.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"iii10","DOI":"10.1093\/ndt\/gfv138.06","article-title":"JTZ-951, an oral novel HIF-PHD inhibitor, elevates hemoglobin in Japanese anemic patients with chronic kidney disease receiving maintenance hemodialysis [abstract no: FO019]","volume":"30","author":"Akizawa","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0156|cit156","first-page":"171","article-title":"Enarodustat (JTZ-951) , an oral HIF-PH inhibitor, elevates and maintains hemoglobin levels over 30 weeks in Japanese anemic patients with CKD not on dialysis [abstract no: TH-PO225]","volume":"29","author":"Akizawa","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD013751.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000496929","article-title":"A placebo-controlled, randomized trial of enarodustat in patients with chronic kidney disease followed by long-term trial","volume":"49","author":"Akizawa","year":"2019","journal-title":"American Journal of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0158|cit158","first-page":"171","article-title":"Enarodustat (JTZ-951), an oral HIF-PH inhibitor, maintains hemoglobin levels switching from ESAs over 30 weeks in Japanese anemic patients with CKD receiving maintenance hemodialysis [abstract no: TH-PO226]","volume":"29","author":"Akizawa","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD013751.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000500487","article-title":"Enarodustat, conversion and maintenance therapy for anemia in hemodialysis patients: a randomized, placebo-controlled phase 2b trial followed by long-term trial","volume":"143","author":"Akizawa","year":"2019","journal-title":"Nephron"},{"issue":"2","key":"10.1002\/14651858.CD013751.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/1744-9987.12888","article-title":"Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: a randomized, phase 3, multicenter, open-label study","volume":"24","author":"Akizawa","year":"2020","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0161|cit161","first-page":"99","article-title":"Phase 3, multicenter, open-label study of intermittent oral roxadustat in peritoneal dialysis CKD patients with anemia [abstract no: SA-OR075]","volume":"29","author":"Akizawa","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0162|cit162","first-page":"822","article-title":"Phase 3, multicenter, randomized, open-label, non-comparative study of intermittent oral roxadustat in ESA-naive CKD patients not on dialysis in Japan [abstract no: SA-PO226]","volume":"30","author":"Akizawa","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD013751.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000508100","article-title":"A phase 3, multicenter, randomized, two-arm, open-label study of intermittent oral dosing of roxadustat for the treatment of anemia in Japanese erythropoiesis-stimulating agent-naive chronic kidney disease patients not on dialysis","volume":"144","author":"Akizawa","year":"2020","journal-title":"Nephron"},{"issue":"6","key":"10.1002\/14651858.CD013751.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/1744-9987.13468","article-title":"Oral roxadustat three times weekly in ESA-naive and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies","volume":"24","author":"Akizawa","year":"2020","journal-title":"Therapeutic Apheresis & Dialysis"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0165|cit165","unstructured":"Anemia studies in CKD: erythropoiesis via a novel prolyl hydroxylase inhibitor (PHI) daprodustat- iron (ASCEND: Fe) www.clinicaltrials.gov\/show\/NCT03457701"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0166|cit166","unstructured":"Anemia study in chronic kidney disease (CKD): erythropoiesis via a novel prolyl hydroxylase inhibitor (PHI) daprodustat-blood pressure (ASCEND-BP) www.clinicaltrials.gov\/show\/NCT03029247"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0167|cit167","first-page":"889","article-title":"A 29-day safety, efficacy, and pharmacodynamic study of a hypoxia-inducible factor prolyl hydroxylase inhibitor, daprodustat, administered TIW in anemic subjects on hemodialysis (HD) [abstract no: SA-PO811]","volume":"28","author":"Bailey","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD013751.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/s12882-019-1547-z","article-title":"A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis","volume":"20","author":"Bailey","year":"2019","journal-title":"BMC Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0169|cit169","first-page":"91A","article-title":"Hypoxia inducing factor prolyl hydroxylase inhibitor FG-4592 corrects anemia in peritoneal dialysis [abstract no: SA-OR087]","volume":"24","author":"Besarab","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD013751.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1681\/ASN.2015030241","article-title":"Roxadustat (FG-4592): correction of anemia in incident dialysis patients","volume":"27","author":"Besarab","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0171|cit171","first-page":"21A","article-title":"FG-4592, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, corrects anemia without iron supplementation in incident dialysis patients [abstract no: TH-OR096]","volume":"23","author":"Besarab","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0172|cit172","first-page":"304a","article-title":"Impact of iron regimen on iron indices and hepcidin during roxadustat anemia correction in incident dialysis patients [abstract no: TH-PO847]","volume":"25","author":"Besarab","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0173|cit173","first-page":"590A","article-title":"Hemodialysis has minimal impact on the pharmacokinetics of AKB-6548, a once-daily oral inhibitor of hypoxia inducible factor prolyl-hydroxylases (HIFPHs) for the treatment of anemia related to chronic kidney disease (CKD) [abstract no: FR-PO952]","volume":"25","author":"Buch","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0174|cit174","article-title":"Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients","author":"Nangaku","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0175|cit175","first-page":"171","article-title":"Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of CKD [abstract no: TH-PO228]","volume":"29","author":"Nangaku","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD013751.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/j.ajkd.2020.02.354","article-title":"Impact of vadadustat on iron regulation in Japanese subjects with chronic kidney disease (CKD) [abstract no: 352]","volume":"75","author":"Solinsky","year":"2020","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0177|cit177","unstructured":"A four-week, phase IIa, randomized, active-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of switching subjects from a stable dose of recombinant human erythropoietin to GSK1278863 in hemodialysis-dependent subjects with anaemia associated with chronic kidney disease - 4 week switch study in HD subjects www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2012-004049-34 2013"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0178|cit178","unstructured":"A 4 week phase IIa, randomized, active-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of switching subjects from a stable dose of recombinant human erythropoietin to GSK1278863 in hemodialysis-dependent subjects with anemia associated with chronic kidney disease www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-004049-34\/results 2013"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0179|cit179","unstructured":"A four-week phase IIa, randomized, double-blind, placebo controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in subjects with anemia associated with chronic kidney disease who are not taking recombinant human erythropoietin and are not undergoing dialysis www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-004050-29\/results 2012"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0180|cit180","unstructured":"A 29-day, randomized, double-blinded, placebo-controlled, parallel-group, multi-center study to evaluate the efficacy, safety and pharmacokinetics of three-times weekly dosing of GSK1278863 in hemodialysis-dependent subjects with anemia associated with chronic kidney disease who are switched from a stable dose of an erythropoiesis-stimulating agent www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2015-004790-32"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD013751.pub2-BIB0181|cit181","first-page":"763A","article-title":"Preliminary results from a randomized, single-blind, placebo-controlled trial of FG-4592, a novel hypoxia inducible factor prolyl hydroxylase inhibitor, in CKD anemia [abstract no: SU-PO806]","volume":"18","author":"Frohna","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0182|cit182","first-page":"318A","article-title":"Vadadustat maintains hemoglobin (Hb) levels in dialysis-dependent chronic kidney disease (DD-CKD) patients independent of systemic inflammation or prior dose of erythropoiesis-stimulating agent (ESA) [abstract no: TH-PO960]","volume":"27","author":"Haase","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013751.pub2-BIB0183|cit183","first-page":"iii22","article-title":"Controlled hemoglobin response in a double-blind, placebo-controlled trial of AKB-6548 in subjects with chronic kidney disease [abstract no: SO051]","volume":"29","author":"Hartman","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0184|cit184","first-page":"56A","article-title":"AKB-6548, a new hypoxia-inducible factor prolyl hydroxylase inhibitor, increases hemoglobin in chronic kidney disease patients without increasing basal erythropoietin levels [abstract no: FR-OR116]","volume":"23","author":"Shalwitz","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD013751.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1681\/ASN.2014111139","article-title":"Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia","volume":"27","author":"Holdstock","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD013751.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1681\/ASN.2014111139","article-title":"Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia","volume":"27","author":"Holdstock","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0187|cit187","first-page":"6B","article-title":"Four-week safety, efficacy and pharmacodynamic study of hypoxia-inducible factor (HIF)-prolyl inhibitor GSK1278863 in anemic hemodialysis subjects switching from recombinant human erythropoietin [abstract no: SA-PO1092]","volume":"24","author":"Meadowcroft","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD013751.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000464476","article-title":"Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease","volume":"45","author":"Martin","year":"2017","journal-title":"American Journal of Nephrology"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0189|cit189","unstructured":"Dose escalation study to investigate safety, tolerability, pharmacodynamics, and pharmacokinetics of BAY85-3934 in subjects with chronic kidney disease (CKD) www.clinicaltrials.gov\/show\/NCT01679587"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0190|cit190","unstructured":"Yamamoto H Safety, tolerability, PK & PD study of JTZ-951 in anemic subjects with end-stage renal disease www.clinicaltrials.gov\/show\/NCT01971164"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0191|cit191","unstructured":"Study to evaluate the pharmacokinetics, pharmacodynamics, and safety of vadadustat in hemodialysis subjects with anemia associated with chronic kidney disease www.clinicaltrials.gov\/show\/NCT03992066"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0192|cit192","unstructured":"Evaluate the efficacy and safety of multiple roxadustat dosing regimens for the treatment of anemia in dialysis subjects with chronic kidney disease www.clinicaltrials.gov\/show\/NCT04059913"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"iii293","DOI":"10.1093\/ndt\/gfv182.06","article-title":"JTZ-951, a novel HIF-PHD inhibitor, demonstrates increases in hemoglobin, iron mobilization, reproducible pharmacokinetics, and safety following once daily administration for 15 days in patients with anemia receiving hemodialysis [abstract no: FP658]","volume":"30","author":"Pai","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"7 Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1016\/j.ekir.2019.05.1131","article-title":"A phase II trial to assess safety, tolerability and efficacy of phd-2 inhibitor (desidustat-zyan1) in the treatment of anemia in pre-dialysis chronic kidney disease patients [abstract no: MON-318]","volume":"4","author":"Parmar","year":"2019","journal-title":"Kidney International Reports"},{"issue":"6","key":"10.1002\/14651858.CD013751.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000500232","article-title":"Outcomes of desidustat treatment in people with anemia and chronic kidney disease: a phase 2 study","volume":"49","author":"Parmar","year":"2019","journal-title":"American Journal of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD013751.pub2-BIB0196|cit196","first-page":"A80","article-title":"Evaluation of FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor, to treat anemia in hemodialysis patients [abstract no: 253]","volume":"57","author":"Provenzano","year":"2011","journal-title":"American Journal of Kidney Diseases"},{"issue":"11","key":"10.1002\/14651858.CD013751.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/jcph.1648","article-title":"Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for treatment of anemia in chronic kidney disease: a placebo-controlled study of pharmacokinetic and pharmacodynamic profiles in hemodialysis patients","volume":"60","author":"Provenzano","year":"2020","journal-title":"Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD013751.pub2-BIB0198|cit198","first-page":"A80","article-title":"Pharmacokinetics of oral FG-4592 to treat anemia in hemodialysis (HD) patients (PTS) [abstract no: 254]","volume":"57","author":"Provenzano","year":"2011","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013751.pub2-BIB0199|cit199","first-page":"ii144","article-title":"Evaluation of hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for hemoglobin correction and maintenance in nondialysis chronic kidney disease patients for 16 and 24 weeks [abstract no: FP215]","volume":"27","author":"Besarab","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013751.pub2-BIB0200|cit200","first-page":"196A","article-title":"FG-4592 oral hypoxia-inducible factor prolyl hydroxylase inhibitor corrects anemia in nondialysis CKD patients without IV iron [abstract no: TH-PO364]","volume":"22","author":"Besarab","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD013751.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2215\/CJN.06890615","article-title":"Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD","volume":"11","author":"Provenzano","year":"2016","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD013751.pub2-BIB0202|cit202","first-page":"v195","article-title":"Pharmacological stabilization of HIF increased hemoglobin concentration in anemic patients with chronic kidney disease [abstract no: MO24]","volume":"20","author":"Wiecek","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0203|cit203","unstructured":"Study of vadadustat in hemodialysis patients with anemia switching from epoetin alfa (FO2RWARD-2) www.clinicaltrials.gov\/show\/NCT03799627"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0204|cit204","unstructured":"Anemia study in chronic kidney disease (CKD) : erythropoiesis via a novel prolyl hydroxylase inhibitor (PHI) daprodustat -forearm blood flow (ASCEND-FBF) www.clinicaltrials.gov\/show\/NCT03446612"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0205|cit205","unstructured":"Kansagra K Desidustat in the treatment of anemia in chronic kidney disease (CKD) ctri.nic.in\/Clinicaltrials\/showallp.php?mid1=33329&EncHid=&userName=CTRI\/2019\/06\/019635"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0206|cit206","unstructured":"Kansagra K Desidustat in the treatment of anemia in CKD ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=36915&EncHid=&userName=CTRI\/2019\/12\/022312"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0207|cit207","unstructured":"Lee JW A study to evaluate efficacy and safety of JTZ-951 compared to darbepoetin alfa in Korean renal anemia patients receiving hemodialysis www.clinicaltrials.gov\/show\/NCT04027517"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0208|cit208","unstructured":"Liu H Evaluate the efficacy and safety of roxadustat for the treatment of anemia and risks of cardiovascular and cerebrovascular events in ESRD newly initiated dialysis patients www.clinicaltrials.gov\/show\/NCT04134026"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0209|cit209","unstructured":"Trial evaluating the efficacy and safety of oral vadadustat once daily (QD) and three times weekly (TIW) for the maintenance treatment of anemia in hemodialysis subjects converting from erythropoiesis-stimulating agents (ESAs) www.clinicaltrials.gov\/show\/NCT04313153"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0210|cit210","unstructured":"A phase 3, multicenter, randomized, open-label active-controlled study of the efficacy and safety of FG-4592 in the treatment of anemia in incident-dialysis patients www.ins.gob.pe\/ensayosclinicos\/rpec\/recuperarECPBNuevoEN.asp?numec=038-14"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0211|cit211","unstructured":"Nazar AL A randomized, active-controlled clinical trial to evaluate the efficacy and safety of desidustat versus darbepoetin for the treatment of anemia in patients with chronic kidney disease (CKD) who are not on dialysis slctr.lk\/trials\/slctr-2019-032"},{"issue":"10","key":"10.1002\/14651858.CD013751.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD013751.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1681\/ASN.2010010116","article-title":"Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD","volume":"21","author":"Bernhardt","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD013751.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/j.1523-1755.2005.00226.x","article-title":"Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program","volume":"67","author":"El-Achkar","year":"2005","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0215|cit215","unstructured":"Cardiovascular and Renal Drugs Advisory Committee Meeting July 15, 2021 Roxadustat www.fda.gov\/media\/150728\/download"},{"issue":"9889","key":"10.1002\/14651858.CD013751.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"issue":"10225","key":"10.1002\/14651858.CD013751.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","journal-title":"Lancet"},{"issue":"10159","key":"10.1002\/14651858.CD013751.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [Erratum in: Lancet. 2019 Jun 22;393(10190):e44]","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","journal-title":"Lancet"},{"issue":"7650","key":"10.1002\/14651858.CD013751.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD013751.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD013751.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.kisu.2020.12.002","article-title":"Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease","volume":"11","author":"Haase","year":"2021","journal-title":"Kidney Int Suppl (2011)"},{"issue":"7414","key":"10.1002\/14651858.CD013751.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0223|cit223","doi-asserted-by":"crossref","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"issue":"4","key":"10.1002\/14651858.CD013751.pub2-BIB0224|cit224","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group","year":"2012","journal-title":"Kidney International Supplements"},{"issue":"1","key":"10.1002\/14651858.CD013751.pub2-BIB0225|cit225","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","journal-title":"Kidney International Supplements"},{"issue":"4","key":"10.1002\/14651858.CD013751.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ncb3330","article-title":"The ever expanding role of HIF in tumour and stromal biology","volume":"18","author":"LaGory","year":"2016","journal-title":"Nature Cell Biology"},{"issue":"2","key":"10.1002\/14651858.CD013751.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"65\u201373","DOI":"10.1159\/000504850","article-title":"Treatment of renal anemia with roxadustat: advantages and achievement","volume":"6","author":"Li","year":"2020","journal-title":"Kidney Diseases"},{"issue":"12","key":"10.1002\/14651858.CD013751.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"4635\u201344","DOI":"10.1172\/JCI63924","article-title":"Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis","volume":"122","author":"Liu","year":"2012","journal-title":"Journal of Clinical Investigation"},{"issue":"3","key":"10.1002\/14651858.CD013751.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1681\/ASN.V103610","article-title":"Hematocrit level and associated mortality in hemodialysis patients","volume":"10","author":"Ma","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD013751.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s41687-020-00215-8","article-title":"Symptoms and impacts in anemia of chronic kidney disease","volume":"4","author":"Mathias","year":"2020","journal-title":"Journal of Patient-Reported Outcomes"},{"issue":"2-3","key":"10.1002\/14651858.CD013751.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"78\u201386","DOI":"10.1159\/000243791","article-title":"The role of hepcidin in iron metabolism","volume":"122","author":"Nemeth","year":"2009","journal-title":"Acta Haematologica"},{"issue":"9559","key":"10.1002\/14651858.CD013751.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0140-6736(07)60194-9","article-title":"Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis","volume":"369","author":"Phrommintikul","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD013751.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2215\/CJN.06890615","article-title":"Oral hypoxia-inducible factor prolyl hydroxylase inhibitor Roxadustat (FG-4592) for the treatment of anemia in patients with CKD","volume":"11","author":"Provenzano","year":"2016","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"3","key":"10.1002\/14651858.CD013751.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MOH.0000000000000494","article-title":"New insights into the links between hypoxia and iron homeostasis","volume":"26","author":"Renassia","year":"2019","journal-title":"Current Opinion in Hematology"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0235|cit235","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0236|cit236","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD013751.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1172\/JCI122359","article-title":"Hepatic hepcidin\/intestinal HIF-2\u03b1 axis maintains iron absorption during iron deficiency and overload","volume":"129","author":"Schwartz","year":"2019","journal-title":"Journal of Clinical Investigation"},{"issue":"6","key":"10.1002\/14651858.CD013751.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1056\/NEJMra1011165","article-title":"Oxygen sensing, homeostasis, and disease [Erratum in: N Engl J Med. 2011 Sep 8;365(10):968]","volume":"365","author":"Semenza","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0239|cit239","unstructured":"The SONG Handbook Version 1.0 www.songinitiative.org\/reports-and-publications\/ 2017"},{"issue":"1","key":"10.1002\/14651858.CD013751.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12882-020-01746-4","article-title":"Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data","volume":"21","author":"Haalen","year":"2020","journal-title":"BMC Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD013751.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/0886022X.2020.1811121","article-title":"Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients","volume":"42","author":"Wang","year":"2020","journal-title":"Renal Failure"},{"issue":"8","key":"10.1002\/14651858.CD013751.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1007\/s11136-019-02173-1","article-title":"The impact of progressive chronic kidney disease on health-related quality of life: A 12-year community cohort study","volume":"28","author":"Wyld","year":"2019","journal-title":"Quality of Life Research"},{"key":"10.1002\/14651858.CD013751.pub2-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.2147\/DDDT.S175887","article-title":"The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease","volume":"12","author":"Zhong","year":"2018","journal-title":"Drug Design, Development & Therapy"},{"issue":"10","key":"10.1002\/14651858.CD013751.pub2-BIB0244|cit244","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013751","article-title":"Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease","author":"Natale","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T15:41:48Z","timestamp":1727883708000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013751.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":244,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013751.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]}}}